Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm
· smallcaps.com.au
Recce expands Phase 3 diabetic foot infection trial with R327G active comparator arm, pursuing non-inferiority vs antibiotics; interim data after 104 patients.
Recce Pharmaceuticals (ASX: RCE) has received Human Research Ethics Committee (HREC) approval to expand its pivotal Australian Phase 3 trial of RECCE 327 topica...